Introduction Over the last decade, tranexamic acid (TXA) has been incorporated into
treatment algorithms for a multitude of emergent conditions and the evidence surrounding its …

In trauma patients, bleeding can lead to coagulopathy, hemorrhagic shock, and multiorgan
failure, and therefore is of fundamental significance in regard to early morbidity. We …

Importance The early use of tranexamic acid (TXA) has demonstrated benefit among some
trauma patients in hemorrhagic shock. The association between TXA administration and …

Introduction Tranexamic acid (TXA) is a potent antifibrinolytic drug that inhibits the activation
of plasmin by plasminogen. While not a new medication, TXA has quickly gained traction …

Background Early hemorrhage control is important in trauma‐related death prevention.
Tranexamic acid (TXA) has shown to be beneficial in patients in hemorrhagic shock …

Introduction Trauma during pregnancy is the leading cause of non-obstetric maternal death
and complicates up to 5%-7% of pregnancies. This systematic review without meta-analysis …

Background Trauma is a major cause of morbidity and mortality in older adults and will
become more common as the population ages. Tranexamic acid (TXA) is a lysine analogue …

INTRODUCTION Tranexamic acid (TXA) or trans-4-amino-methyl-cyclohexane-carbonic
acid is a synthetic analog derivative of amino acid lysine that inhibits fibrinolysis by …

OBJECTIVES: Tranexamic acid (TXA) administration confers a survival benefit in bleeding
trauma patients; however, data regarding its use in pediatric patients are limited. This study …

Objective Tranexamic acid (TXA) has demonstrated a reduction in all-cause mortality in
trauma patients with hemorrhage. Administering TXA in the prehospital setting presents …